Prime Medicine, Inc. — Q1 2023 Form 10-Q
Business context and reporting period
For the three months ended March 31, 2023. Prime Medicine is a clinical-stage? No: the company is an early-stage biotechnology company developing Prime Editing gene-editing therapies. It reported 18 investigational programs, all in research or preclinical development, and had not initiated clinical development or generated product revenue.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $30.9 million | $13.7 million |
| General and administrative expense | $9.2 million | $6.2 million |
| Total operating expenses / operating loss | $40.0 million | $19.9 million |
| Net loss | $39.4 million | $23.8 million |
| Net loss per share, basic and diluted | $0.44 | $1.58 |
| Net cash used in operating activities | $41.6 million | $50.8 million |
At March 31, 2023, cash and cash equivalents were $133.5 million and short-term investments were $116.1 million, including $6.1 million of Beam equity securities. Cash, cash equivalents and investments totaled $249.5 million, excluding restricted cash, and $263.0 million including restricted cash. Total current assets were $253.5 million versus current liabilities of $23.9 million. Total liabilities were $38.1 million; the filing reports no borrowings or other financial debt, but does report operating lease liabilities.
Cash, cash equivalents and restricted cash declined $54.2 million during the quarter. Investing activities used $12.7 million, including $2.0 million for property and equipment and net purchases of investments. No meaningful operating margin comparison is available because the company had no product revenue.
Changes versus the prior comparable period
Operating expenses increased $20.1 million year over year. R&D expense rose $17.2 million, primarily from higher lab supplies ($6.9 million), personnel costs ($5.6 million), facility costs ($2.8 million) and professional and consultant fees ($1.4 million). G&A increased $2.9 million, mainly due to facility and professional costs. Net loss widened by $15.6 million. The smaller reported loss per share in 2023 reflects the substantially higher weighted-average share count after the 2022 IPO and preferred-stock conversion; the 2022 common-stockholder loss also included a preferred dividend.
Operating cash use was lower than in Q1 2022, largely because the prior-year period included a larger reduction in accrued liabilities. The company’s IPO was completed in October 2022 and generated $180.2 million in net proceeds; no material change to the stated use of those proceeds was reported.
Outlook, risks and unusual items
- Management said existing cash, cash equivalents and short-term investments were expected to fund operating expenses and capital expenditure requirements into 2025. The filing also states the resources should cover at least the next 12 months; both estimates depend on assumptions that could prove incorrect. Additional financing will be needed to support ongoing operations and the company has no committed external funding source.
- Management expects losses, negative operating cash flow and substantially higher R&D spending for the foreseeable future, particularly as programs advance toward preclinical work and clinical trials. Profitability and product revenue remain uncertain and may never be achieved.
- The company described Prime Editing as novel and not clinically validated. Key risks include preclinical or clinical failure, delivery and manufacturing challenges, off-target or other safety effects, evolving regulation, competition, reliance on third parties, and dependence on licensed intellectual property and collaborators.
- A planned Cambridge laboratory and office lease at 60 First Street had not commenced at quarter-end. The company expected rent to start 11 months after taking possession and occupancy in 2024, with approximately $208.7 million of payments over the ten-year term. This lease was excluded from reported lease liabilities. In April 2023, the company also amended its 21 Erie Street lease; the amendment was not reflected at March 31.
- Other income included $2.1 million, primarily interest income, partly offset by a $1.7 million fair-value loss on the related-party Beam investment. The comparable-period Beam investment loss was $4.5 million.
- No legal proceeding was reported as probable to have a material adverse effect. The filing discusses industry-wide bank liquidity risks and states the company was not a borrower or party to instruments with the failed banks identified.
Important facts for investors to verify
- Whether the projected cash runway into 2025 remains supportable as spending rises and programs advance.
- Program-level preclinical progress, proof-of-concept milestones, and anticipated timing for IND-enabling studies and clinical development.
- The eventual commencement and financial impact of the approximately $208.7 million 60 First Street lease and the April 2023 lease amendment.
- Future financing needs, potential dilution, and any changes to collaboration, licensing, or intellectual-property rights.
- Whether subsequent disclosures identify material changes in safety, regulatory, manufacturing, competitive, or liquidity risks.